Trial Outcomes & Findings for Brief Educational Video for Patients Prescribed LTBI Treatment (NCT NCT05412212)
NCT ID: NCT05412212
Last Updated: 2026-07-09
Results Overview
Proportion of patients prescribed LTBI treatment who complete the treatment within one year of treatment prescription
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
1894 participants
Primary outcome timeframe
1 year after treatment prescription
Results posted on
2026-07-09
Participant Flow
Adults at Kaiser Permanente Southern California prescribed LTBI treatment were randomized to receive messages with the video link (intervention) or no intervention (control).
Participant milestones
| Measure |
LTBI Video Intervention
Patients randomized to the intervention group were sent an invitation with a link to watch a brief (\~3 minute video) about the importance of initiating and completing LTBI treatment.
|
Standard Care
Patients randomized to receive standard of care did not receive any messages or have any contact with the research team.
|
|---|---|---|
|
Overall Study
STARTED
|
1398
|
496
|
|
Overall Study
COMPLETED
|
1398
|
496
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Brief Educational Video for Patients Prescribed LTBI Treatment
Baseline characteristics by cohort
| Measure |
Total
n=1894 Participants
Total of all reporting groups
|
LTBI Video Intervention
n=1398 Participants
Patients randomized to the intervention group were sent an invitation with a link to watch a brief (\~3 minute video) about the importance of initiating and completing LTBI treatment.
|
Standard Care
n=496 Participants
Patients randomized to receive standard of care did not receive any messages or have any contact with the research team.
|
|---|---|---|---|
|
Race/Ethnicity, Customized
Black
|
138 Participants
n=40 Participants
|
98 Participants
n=20 Participants
|
40 Participants
n=20 Participants
|
|
Age, Customized
18-35
|
517 Participants
n=40 Participants
|
374 Participants
n=20 Participants
|
143 Participants
n=20 Participants
|
|
Age, Customized
36-49
|
586 Participants
n=40 Participants
|
437 Participants
n=20 Participants
|
149 Participants
n=20 Participants
|
|
Age, Customized
50-64
|
503 Participants
n=40 Participants
|
366 Participants
n=20 Participants
|
137 Participants
n=20 Participants
|
|
Age, Customized
65-74
|
217 Participants
n=40 Participants
|
165 Participants
n=20 Participants
|
52 Participants
n=20 Participants
|
|
Age, Customized
>=75
|
71 Participants
n=40 Participants
|
56 Participants
n=20 Participants
|
15 Participants
n=20 Participants
|
|
Sex: Female, Male
Female
|
1129 Participants
n=40 Participants
|
838 Participants
n=20 Participants
|
291 Participants
n=20 Participants
|
|
Sex: Female, Male
Male
|
765 Participants
n=40 Participants
|
560 Participants
n=20 Participants
|
205 Participants
n=20 Participants
|
|
Race/Ethnicity, Customized
Asian
|
361 Participants
n=40 Participants
|
258 Participants
n=20 Participants
|
103 Participants
n=20 Participants
|
|
Race/Ethnicity, Customized
Hispanic
|
1023 Participants
n=40 Participants
|
768 Participants
n=20 Participants
|
255 Participants
n=20 Participants
|
|
Race/Ethnicity, Customized
White
|
245 Participants
n=40 Participants
|
183 Participants
n=20 Participants
|
62 Participants
n=20 Participants
|
|
Race/Ethnicity, Customized
Other/unknown
|
127 Participants
n=40 Participants
|
91 Participants
n=20 Participants
|
36 Participants
n=20 Participants
|
|
Age, years (median)
|
45 years
n=40 Participants
|
45 years
n=20 Participants
|
44 years
n=20 Participants
|
|
Country of birth
Born in high TB incidence country
|
724 Participants
n=40 Participants
|
533 Participants
n=20 Participants
|
191 Participants
n=20 Participants
|
|
Country of birth
Not born in high TB incidence country
|
768 Participants
n=40 Participants
|
570 Participants
n=20 Participants
|
198 Participants
n=20 Participants
|
|
Country of birth
Missing
|
402 Participants
n=40 Participants
|
295 Participants
n=20 Participants
|
107 Participants
n=20 Participants
|
|
Weighted Charlson Comorbidity Index (mean)
|
1.1 scores on a scale
STANDARD_DEVIATION 1.9 • n=40 Participants
|
1.1 scores on a scale
STANDARD_DEVIATION 1.8 • n=20 Participants
|
1.0 scores on a scale
STANDARD_DEVIATION 1.9 • n=20 Participants
|
|
Weighted Charlson Comorbidity Index (median)
|
0 scores on a scale
n=40 Participants
|
0 scores on a scale
n=20 Participants
|
0 scores on a scale
n=20 Participants
|
|
Immunosuppressants in prior year
|
109 Participants
n=40 Participants
|
82 Participants
n=20 Participants
|
27 Participants
n=20 Participants
|
|
High-dose steroids in prior year
|
16 Participants
n=40 Participants
|
13 Participants
n=20 Participants
|
3 Participants
n=20 Participants
|
|
Organ transplant, ever
|
9 Participants
n=40 Participants
|
7 Participants
n=20 Participants
|
2 Participants
n=20 Participants
|
|
Dialysis, ever
|
61 Participants
n=40 Participants
|
45 Participants
n=20 Participants
|
16 Participants
n=20 Participants
|
|
HIV diagnosis, ever
|
30 Participants
n=40 Participants
|
22 Participants
n=20 Participants
|
8 Participants
n=20 Participants
|
|
LTBI treatment prescribed
Rifampin
|
1295 Participants
n=40 Participants
|
955 Participants
n=20 Participants
|
340 Participants
n=20 Participants
|
|
LTBI treatment prescribed
Isoniazid
|
444 Participants
n=40 Participants
|
329 Participants
n=20 Participants
|
115 Participants
n=20 Participants
|
|
LTBI treatment prescribed
Isoniazid + rifampin
|
65 Participants
n=40 Participants
|
46 Participants
n=20 Participants
|
19 Participants
n=20 Participants
|
|
LTBI treatment prescribed
Isoniazid + rifapentine
|
75 Participants
n=40 Participants
|
56 Participants
n=20 Participants
|
19 Participants
n=20 Participants
|
|
LTBI treatment prescribed
Other
|
15 Participants
n=40 Participants
|
12 Participants
n=20 Participants
|
3 Participants
n=20 Participants
|
|
Drug coverage at time of prescription
|
1856 Participants
n=40 Participants
|
1369 Participants
n=20 Participants
|
487 Participants
n=20 Participants
|
PRIMARY outcome
Timeframe: 1 year after treatment prescriptionProportion of patients prescribed LTBI treatment who complete the treatment within one year of treatment prescription
Outcome measures
| Measure |
LTBI Video Intervention
n=1398 Participants
Patients randomized to the intervention group were sent an invitation with a link to watch a brief (\~3 minute video) about the importance of initiating and completing LTBI treatment.
|
Standard Care
n=496 Participants
Patients randomized to receive standard of care did not receive any messages or have any contact with the research team.
|
|---|---|---|
|
Treatment Completion
Yes
|
561 Participants
|
206 Participants
|
|
Treatment Completion
No
|
837 Participants
|
290 Participants
|
Adverse Events
LTBI Video Intervention
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Standard Care
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place